These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30822243)

  • 1. Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study.
    Spila-Alegiani S; Trotta F; Da Cas R; Rossi M; Venegoni M; Traversa G
    COPD; 2018 Oct; 15(5):418-423. PubMed ID: 30822243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study.
    Trotta F; Spila-Alegiani S; Da Cas R; Rajevic M; Conti V; Venegoni M; Rossi M; Traversa G
    PLoS One; 2017; 12(4):e0176276. PubMed ID: 28430820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.
    Trotta F; Da Cas R; Rajevic M; Rossi M; Traversa G
    BMJ Open; 2015 May; 5(5):e006619. PubMed ID: 26009573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
    Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIOtropium Safety and Performance In Respimat
    Zhong N; Moon HS; Lee KH; Mahayiddin AA; Boonsawat W; Isidro MG; Bai C; Mueller A; Metzdorf N; Anzueto A
    Respirology; 2016 Nov; 21(8):1397-1403. PubMed ID: 27490162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
    Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
    Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
    BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.
    Wise R; Calverley PM; Dahl R; Dusser D; Metzdorf N; Müller A; Fowler A; Anzueto A
    NPJ Prim Care Respir Med; 2015 Nov; 25():15067. PubMed ID: 26540491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
    Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
    Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR
    Anzueto A; Calverley PMA; Mueller A; Metzdorf N; Haensel M; Jardim JR; Pizzichini E; Giraldo H; Ramirez-Venegas A; Giugno ER
    Arch Bronconeumol (Engl Ed); 2018 Mar; 54(3):140-148. PubMed ID: 29317111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
    Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
    Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
    Dahl R; Kaplan A
    BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of tiotropium Respimat in the treatment of chronic obstructive pulmonary disease: systematic review].
    Cai HD; Hou J; Lyu YN; Xiong L; Lu MZ; Wu SL
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Aug; 40(8):596-603. PubMed ID: 28810313
    [No Abstract]   [Full Text] [Related]  

  • 14. Tiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.
    Schmiedl S; Fischer R; Ibanez L; Fortuny J; Thürmann P; Ballarin E; Ferrer P; Sabaté M; Rottenkolber D; Gerlach R; Tauscher M; Reynolds R; Hasford J; Rottenkolber M
    Br J Clin Pharmacol; 2016 Feb; 81(2):379-88. PubMed ID: 26506314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiotropium Respimat inhaler and the risk of death in COPD.
    Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
    N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.
    Wise RA; Anzueto A; Calverley P; Dahl R; Dusser D; Pledger G; Koenen-Bergmann M; Joseph E; Cotton D; Disse B
    Respir Res; 2013 Apr; 14(1):40. PubMed ID: 23547660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bronchodilator Effect of Tiotropium via Respimat
    Ogasawara T; Sakata J; Aoshima Y; Tanaka K; Yano T; Kasamatsu N
    Intern Med; 2017 Sep; 56(18):2401-2406. PubMed ID: 28824055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
    Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
    Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
    Verhamme KM; Afonso A; Romio S; Stricker BC; Brusselle GG; Sturkenboom MC
    Eur Respir J; 2013 Sep; 42(3):606-15. PubMed ID: 23520322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.